Edited by

Edited by is a news outlet that focuses on medical and health-related topics. The team consists of experienced editors and writers who specialize in reporting on the latest developments in medicine, pharmaceuticals, and public health. They aim to provide accurate, timely, and relevant information to healthcare professionals and the general public alike.

Biography:  https://www.medscape.com/features/slideshow/women-physicians

83%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • Higher risk of NAION in patients prescribed semaglutide compared to non-GLP-1 RA medications for diabetes or obesity
  • In the population of patients who were overweight or obese, there were 20 NAION events in semaglutide cohort vs. 3 in non-GLP-1 RA cohort
  • In the population with Type 2 Diabetes, there were 17 NAION events in semaglutide cohort vs. 6 in non-GLP-1 RA antidiabetic medications cohort

Deceptions

45%

Examples:

  • In patients with overweight or obesity, semaglutide again was linked to a higher risk for NAION (HR, 7.64; 95% CI, 2.21-26.36.).
  • Patients with type 2 diabetes, overweight, or obesity taking the glucagon-like peptide receptor agonist (GLP-1 RA) semaglutide appear to have an increased risk for an uncommon condition that can cause vision loss.
  • These findings suggest that switching from smoking to vaping indoors may substantially reduce, but not eliminate, children's secondhand exposure to nicotine and other noxious substances.

Recent Articles

New Study: Children's Secondhand Exposure to Nicotine from E-Cigarettes vs Tobacco Smoke - Comparative Findings

New Study: Children's Secondhand Exposure to Nicotine from E-Cigarettes vs Tobacco Smoke - Comparative Findings

Broke On: Friday, 12 July 2024 A new study in the Journal of the American Medical Association Network Open reveals that children living with e-cigarette users absorb 84% less nicotine through secondhand aerosols than those exposed to tobacco smoke. However, vaping still poses risks for children, particularly regarding lung development.
Semaglutide Linked to Increased Risk of NAION: Study Finds Hazard Ratios of 4.28 and 7.64 in Type 2 Diabetes and Overweight Populations, Respectively

Semaglutide Linked to Increased Risk of NAION: Study Finds Hazard Ratios of 4.28 and 7.64 in Type 2 Diabetes and Overweight Populations, Respectively

Broke On: Wednesday, 03 July 2024 A recent study published in JAMA Ophthalmology found that patients taking semaglutide, a medication for diabetes and obesity, had a significantly higher risk of developing Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), which can cause vision loss. The incidence rate was 4.28 times higher in type 2 diabetes patients and 7.64 times higher in overweight or obese patients taking semaglutide compared to non-GLP-1 RA medications.